TRCT
ADPT icon

Tower Research Capital (TRC)’s Adaptive Biotechnologies ADPT Stock Holding History

Tower Research Capital (TRC)’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.2K Sell
4,347
-3,129
-42% -$47.9K ﹤0.01% 2239
2026
Q1 		$104K Buy
7,476
+6,174
+474% +$98.4K ﹤0.01% 2145
2025
Q4 		$21.1K Sell
1,302
-3,663
-74% -$59.8K ﹤0.01% 3062
2025
Q3 		$74.3K Sell
4,965
-16,324
-77% -$199K ﹤0.01% 2233
2025
Q2 		$248K Sell
21,289
-7,182
-25% -$65.2K 0.01% 1589
2025
Q1 		$212K Buy
28,471
+27,791
+4,087% +$214K 0.01% 1338
2024
Q4 		$4.08K Sell
680
-15,111
-96% -$83.3K ﹤0.01% 4521
2024
Q3 		$80.8K Buy
15,791
+1,225
+8% +$5.34K ﹤0.01% 2394
2024
Q2 		$52.7K Buy
14,566
+13,384
+1,132% +$42.5K ﹤0.01% 3067
2024
Q1 		$3.79K Sell
1,182
-78,361
-99% -$303K ﹤0.01% 4792
2023
Q4 		$390K Buy
79,543
+69,431
+687% +$317K ﹤0.01% 1573
2023
Q3 		$55.1K Sell
10,112
-3,283
-25% -$21.7K ﹤0.01% 2463
2023
Q2 		$89.9K Sell
13,395
-25,583
-66% -$190K ﹤0.01% 2108
2023
Q1 		$344K Buy
38,978
+38,128
+4,486% +$336K 0.01% 1058
2022
Q4 		$6K Sell
850
-19,264
-96% -$150K ﹤0.01% 4675
2022
Q3 		$143K Buy
20,114
+16,369
+437% +$154K ﹤0.01% 2230
2022
Q2 		$30K Sell
3,745
-17,095
-82% -$150K ﹤0.01% 3364
2022
Q1 		$290K Buy
20,840
+20,026
+2,460% +$315K ﹤0.01% 1484
2021
Q4 		$23K Sell
814
-560
-41% -$17.2K ﹤0.01% 3496
2021
Q3 		$47K Sell
1,374
-7,734
-85% -$280K ﹤0.01% 3009
2021
Q2 		$372K Buy
9,108
+7,649
+524% +$297K 0.01% 1422
2021
Q1 		$59K Sell
1,459
-4,401
-75% -$238K ﹤0.01% 2976
2020
Q4 		$347K Buy
5,860
+4,886
+502% +$252K 0.01% 1284
2020
Q3 		$47K Sell
974
-632
-39% -$26.6K ﹤0.01% 3560
2020
Q2 		$78K Buy
+1,606
New +$58.6K ﹤0.01% 2671
2019
Q4 		– Sell
-54
Closed -$2K – 3450
2019
Q3 		$2K Buy
+54
New +$2.2K ﹤0.01% 3647

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Tower Research Capital (TRC)'s ADPT Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Adaptive Biotechnologies (ADPT) stake by 42% in Q2 2026, selling an estimated $47.9K and leaving 4,347 shares worth $93.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2239.

Tower Research Capital (TRC) first reported a position in ADPT in Q3 2019 and has held it in 26 quarters since. The position peaked at $390K in Q4 2023. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Tower Research Capital (TRC) held 4,347 shares of Adaptive Biotechnologies worth $93.2K as of Q2 2026.
  • Tower Research Capital (TRC) sold 3,129 Adaptive Biotechnologies shares in Q2 2026, an estimated $47.9K.
  • Adaptive Biotechnologies made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2239 holding.
  • Tower Research Capital (TRC) first reported a position in Adaptive Biotechnologies in Q3 2019 and has held it in 26 quarters since.
  • Tower Research Capital (TRC)'s Adaptive Biotechnologies position peaked at $390K in Q4 2023.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.